MKI67 and neuroendocrine carcinoma: Grade 3 NET have been shown to be clinically distinct from NEC, with higher rates of avidity on somatostatin receptor scintigraphy (SRS), lower Ki67, poorer responses to platinum based chemotherapy, and longer survival4–8.